Pharmaceutical composition for resisting mycobacterial infection
Through the combined use of betaquinolin and bedaquiline, the problem of drug resistance in tuberculosis was solved, significantly enhanced the anti-mycobacterial infection activity of betaquinolin, reversed drug resistance, and improved the therapeutic effect.
Patent Information
- Application Number
- CN202411138845.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-19
AI Technical Summary
The drug resistance of tuberculosis is serious, the existing treatment drug selection is limited, the treatment course is long, and the cure rate is low. Especially the drug-resistant strains of bedaquiline and clofazimin are present, making it difficult to effectively treat multidrug-resistant tuberculosis.
The combination of bedaquiline and bedaquiline enhances the anti-mycobacterial infection activity of bedaquiline and forms a pharmaceutical composition to inhibit mycobacterial activity, prevent and treat tuberculosis.
Zyclothiool significantly reduced the minimum inhibitory concentration of bedaquiline, showed 32-fold increase in drug-resistant strains, reversed drug resistance, and improved the therapeutic effect of anti-mycobacterial infection.
Smart Images

Figure BDA0005000170020000101 
Figure BDA0005000170020000111 
Figure BDA0005000170020000121
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to an application of a pharmaceutical composition in resisting mycobacterial infection. Background Art
[0002] Mycobacteria include the Mycobacterium tuberculosis complex (including Mycobacterium tuberculosis, bovine, African, voles, caprine, pinnipedii, suricattae, and mungi), non-tuberculous mycobacteria (NTM), and Mycobacterium leprae.
[0003] Tuberculosis caused by Mycobacterium tuberculosis (MTB) is a chronic respiratory infectious disease that seriously endangers human health. The situation of tuberculosis drug resistance is serious, the drug options for the treatment of drug-resistant tuberculosis are limited, the treatment course is long, and the cure rate is as low as about 63%. In 2019 and 2022, WHO listed bedaquiline and clofazimine as group A and group B drugs in the core drugs for the treatment of multidrug-resistant tuberculosis, respectively, but bedaquiline-resistant strains were soon identified. The research team has discovered clinically resistant strains of the new drug bedaquiline, especially cross-resistant strains of bedaquiline and clofazimine (Rv0678 gene mutation) isolated from tuberculosis patients who have not been exposed and have not used the drug (Xu J, et al. Antimicrob Agents Chemother, 2017). Although mutations in the atpE gene encoding ATP synthase and non-target PepQ genes are associated with bedaquiline resistance, the most commonly reported mutation in the Mycobacterium tuberculosis Rv0678 gene associated with bedaquiline resistance in clinical practice can lead to reduced anti-mycobacterial activity of chemotherapy regimens containing bedaquiline, prolonged treatment cycles, and even treatment failure. Studies have found that Rv0678 mutations can also lead to resistance to group B drugs, clofazimine, and PBTZ169, a new anti-tuberculosis drug in clinical phase II, which are core drugs for the treatment of multidrug-resistant tuberculosis. Studies have found that Rv0678 mutants still have partial cross-resistance to the new generation of more active bedaquiline derivatives (TBAJ-587) and clofazimine derivatives (Xu J, et al. Antimicrob Agents Chemother, 2021; Xu J, et al. Antimicrob Agents Chemother, 2019).
[0004] The Rv0678 gene is a transcriptional repressor of the MmpL5-MmpS5 efflux system, and its mutation can cause overexpression of MmpL5 and MmpS5. Transcriptome and proteomics studies also found that the mutation of Rv0678 caused the expression of MmpL5 and MmpS5 to be more than 2-fold upregulated in bedaquiline-resistant Mycobacterium tuberculosis (Xu J, et al. Antimicrob Agents Chemother, 2023). One of the ways to combat drug resistance caused by drug efflux is to develop drug efflux inhibitors and use them in combination with antibiotics. In the study of the role and function of MmpL5-MmpS5, it was found that in both Mycobacterium smegmatis and Mycobacterium tuberculosis, the co-expression of MmpL5 and MmpS5 can form an efflux pump, leading to bedaquiline resistance, while MmpL5 alone does not work (Li Dongshuo; Wang Bin; Lu Yu; Xu Jian. Expression and Functional Study of Mycobacterium tuberculosis Membrane Protein MmpS5-MmpL5. Chinese Journal of Anti-Tuberculosis 2022; Xu J, et al. Antimicrob Agents Chemother, 2023). This study laid the foundation for the interaction of MmpL5-MmpS5 as a new target.
[0005] Nontuberculous mycobacteria (NTM) were once called atypical mycobacteria, atypical acid-fast bacilli, unclassified mycobacteria, unclassified mycobacteria, anonymous mycobacteria, wild mycobacteria, opportunistic mycobacteria, paratuberculosis, pseudotuberculosis, etc. NTM disease refers to human infection with NTM, which causes lesions in related tissues and organs (Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: anonymous ATS / ERS / ESCMID / IDSA clinical practice guideline [J]. Eur Respir J, 2020, 56 (1): 200053.). NTM disease is a systemic disease that mainly invades lung tissue, but all organ systems in the body can be affected, including systemic poisoning symptoms and local damage (Tang Shenjie, Gao Wen. Clinical Tuberculosis [M]. 2nd edition. Beijing: People's Medical Publishing House, 2019: 1026-1046.). In the absence of species identification results, NTM disease can be misdiagnosed as tuberculosis and bronchiectasis for a long time. NTM causes different bacterial species, affected tissues and organs, and their clinical manifestations vary. In recent years, NTM disease has shown a rapid increase and has become one of the important public health issues threatening human health (Furuuchi K, Morimoto K, Yoshiyama T, et al. Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan [J]. Respir Med, 2019, 152: 74-80.).
[0006] In the field of diagnosis, GeneXpert MTB / RIF has become the main method for rapid diagnosis of tuberculosis and rapid detection of rifampicin resistance; in the field of treatment, the all-oral short-term treatment regimen for multidrug-resistant / rifampicin-resistant tuberculosis (MDR / RR-TB) has become the treatment regimen recommended by the guidelines. However, the proportion of drug-resistant diseases is still increasing, and the lack of rapid diagnostic methods, long treatment courses, and treatment regimens that include injections cannot meet the needs of rapid diagnosis of the disease and also affect patients' compliance with treatment. Therefore, new treatment methods are urgently needed.
[0007] Zuclopenthixol is a thioxanthene derivative that works by blocking dopamine receptors and has significant antipsychotic and sedative effects. Zuclopenthixol was discovered in 1962 and has been used for antipsychotics. It has been marketed in more than 30 countries including Europe, Latin America and Canada. So far, there have been no reports on its activity against Mycobacterium tuberculosis and its combined enhanced anti-mycobacterial infection activity. As the problem of tuberculosis drug resistance becomes more and more serious, it is urgent to develop new treatment strategies to enhance the activity of bedaquiline against mycobacterial infection and reduce the occurrence of new drug resistance. Summary of the invention
[0008] In the present invention, it is found that the combination of zuclopenthixol and bedaquiline can enhance the anti-mycobacterial activity of bedaquiline, and the drug combined with zuclopenthixol and bedaquiline has the effect of anti-mycobacterial infection. Based on this, the present invention is completed.
[0009] In a first aspect, the present invention provides a pharmaceutical composition for resisting mycobacterial infection, the pharmaceutical composition comprising zuclopenthixol and bedaquiline, and the pharmaceutical composition has at least one of the following effects:
[0010] a) inhibiting mycobacterial activity;
[0011] b) Anti-mycobacterial infection;
[0012] c) prevention and / or treatment of diseases caused by mycobacteria.
[0013] Furthermore, the mycobacterium is selected from Mycobacterium tuberculosis, non-tuberculous mycobacteria and / or Mycobacterium leprae.
[0014] Furthermore, the Mycobacterium tuberculosis includes clinical isolates of Mycobacterium tuberculosis, standard strains of Mycobacterium tuberculosis and / or Mycobacterium tuberculosis carried by patients infected with Mycobacterium tuberculosis.
[0015] Furthermore, the Mycobacterium tuberculosis infection includes: primary infection, secondary infection, extrapulmonary infection, and pulmonary infection.
[0016] Furthermore, the diseases caused by Mycobacterium tuberculosis include but are not limited to drug-resistant tuberculosis, non-drug-resistant tuberculosis, pulmonary tuberculosis, extrapulmonary tuberculosis, etc.
[0017] Furthermore, the drug-resistant tuberculosis includes but is not limited to mono-drug-resistant tuberculosis, multi-drug-resistant tuberculosis, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis.
[0018] Furthermore, the pulmonary tuberculosis includes primary pulmonary tuberculosis, secondary pulmonary tuberculosis, blood type disseminated pulmonary tuberculosis, tracheobronchial tuberculosis, tuberculous pleurisy, septic tuberculosis, etc.
[0019] Furthermore, the extrapulmonary tuberculosis includes but is not limited to lymph node tuberculosis, intestinal tuberculosis, renal tuberculosis, bone and joint tuberculosis, etc.
[0020] Furthermore, the Mycobacterium tuberculosis includes multidrug-resistant Mycobacterium tuberculosis and extensively drug-resistant Mycobacterium tuberculosis.
[0021] Furthermore, the Mycobacterium tuberculosis includes Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium cannabinum and Mycobacterium microti.
[0022] Furthermore, the non-tuberculous mycobacteria include but are not limited to Mycobacterium avium (M.avium), Mycobacterium intracellulare (M.intracellulare), Mycobacterium kansasii (M.kansasii), Mycobacterium fortuitum (M.fortuitum), Mycobacterium abscessus (M.abscessus), Mycobacterium ulcerans (M.ulcerans) and / or Mycobacterium marinum (M.marinum) and the like.
[0023] Furthermore, the disease caused by nontuberculous mycobacteria is selected from one or more of NTM lung disease, NTM lymphatic disease, disseminated NTM disease and / or other NTM diseases.
[0024] Furthermore, the pharmaceutical composition may also contain other active ingredients against mycobacterial infection.
[0025] Furthermore, one or more pharmaceutically acceptable carriers may be added to the pharmaceutical composition.
[0026] Furthermore, the pharmaceutical composition can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral solution, injection preparation or aerosol; the above various dosage forms of drugs can be prepared according to conventional methods in the pharmaceutical field.
[0027] Furthermore, the preparation can be one or more of a conventional preparation, a sustained-release preparation, a controlled-release preparation and / or various microparticle delivery systems.
[0028] Furthermore, the tablets may widely use various carriers known in the art, including one or more of diluents and absorbents, wetting agents and binders, disintegrants, disintegration inhibitors, absorption enhancers and / or lubricants.
[0029] Furthermore, the diluent and absorbent include, but are not limited to, one or more of starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose and / or aluminum silicate.
[0030] Furthermore, the wetting agent and adhesive include, but are not limited to, one or more of water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia gum slurry, gelatin slurry, sodium carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and / or polyvinyl pyrrolidone.
[0031] Furthermore, the disintegrant includes, but is not limited to, one or more of dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitan fatty acid ester, sodium dodecyl sulfate, methyl cellulose and / or ethyl cellulose.
[0032] Furthermore, the disintegration inhibitor includes but is not limited to sucrose, tristearin, cocoa butter and / or hydrogenated oil.
[0033] Furthermore, the absorption enhancer includes but is not limited to one or more of quaternary ammonium salts and / or sodium lauryl sulfate.
[0034] Furthermore, the lubricant includes, but is not limited to, one or more of talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin and / or polyethylene glycol.
[0035] Furthermore, the tablets can be further made into coated tablets, including sugar-coated tablets, film-coated tablets, enteric-coated tablets, double-layer tablets and multi-layer tablets.
[0036] Furthermore, the injectable preparation includes, but is not limited to, one or more of a solution, an emulsion, a lyophilized powder injection and / or a suspension.
[0037] Furthermore, the injectable preparation may use all diluents commonly used in the art, including but not limited to one or more of water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol and / or polyoxyethylene sorbitan fatty acid esters.
[0038] Furthermore, in order to prepare an isotonic injection solution, the injection preparation may be added with an appropriate amount of one or more of sodium chloride, glucose, glycerol, conventional cosolvents, buffers and / or pH regulators.
[0039] Furthermore, the various preparations may also add colorants, preservatives, spices, flavoring agents, sweeteners or other materials to the pharmaceutical preparations as needed.
[0040] Furthermore, the pharmaceutical composition can be introduced into the body by physical or chemical methods, such as intramuscularly, intradermally, subcutaneously or intravenously.
[0041] Furthermore, the zuclopenthixol also includes pharmaceutically acceptable salts or esters.
[0042] Furthermore, the pharmaceutical salts include but are not limited to pharmaceutically acceptable salts such as acetate and hydrochloride.
[0043] Furthermore, the pharmaceutical esters include but are not limited to decanoate.
[0044] In a second aspect, the present invention provides a use of zuclopenthixol as a synergist for the anti-mycobacterial infection effect of bedaquiline. When zuclopenthixol is used in combination with bedaquiline, zuclopenthixol can enhance the anti-mycobacterial infection activity of bedaquiline.
[0045] Furthermore, the mycobacterium is selected from Mycobacterium tuberculosis, non-tuberculous mycobacteria and / or Mycobacterium leprae.
[0046] Furthermore, the Mycobacterium tuberculosis includes clinical isolates of Mycobacterium tuberculosis, standard strains of Mycobacterium tuberculosis and / or Mycobacterium tuberculosis carried by patients infected with Mycobacterium tuberculosis.
[0047] Furthermore, the Mycobacterium tuberculosis infection includes: primary infection, secondary infection, extrapulmonary infection, and pulmonary infection.
[0048] Furthermore, the diseases caused by Mycobacterium tuberculosis include but are not limited to drug-resistant tuberculosis, non-drug-resistant tuberculosis, pulmonary tuberculosis, extrapulmonary tuberculosis, etc.
[0049] Furthermore, the drug-resistant tuberculosis includes but is not limited to mono-drug-resistant tuberculosis, multi-drug-resistant tuberculosis, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis.
[0050] Furthermore, the pulmonary tuberculosis includes primary pulmonary tuberculosis, secondary pulmonary tuberculosis, blood type disseminated pulmonary tuberculosis, tracheobronchial tuberculosis, tuberculous pleurisy, septic tuberculosis, etc.
[0051] Furthermore, the extrapulmonary tuberculosis includes but is not limited to lymph node tuberculosis, intestinal tuberculosis, renal tuberculosis, bone and joint tuberculosis, etc.
[0052] Furthermore, the Mycobacterium tuberculosis includes multidrug-resistant Mycobacterium tuberculosis and extensively drug-resistant Mycobacterium tuberculosis.
[0053] Furthermore, the Mycobacterium tuberculosis includes Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium cannabinum and Mycobacterium microti.
[0054] Furthermore, the non-tuberculous mycobacteria include but are not limited to Mycobacterium avium (M.avium), Mycobacterium intracellulare (M.intracellulare), Mycobacterium kansasii (M.kansasii), Mycobacterium fortuitum (M.fortuitum), Mycobacterium abscessus (M.abscessus), Mycobacterium ulcerans (M.ulcerans) and / or Mycobacterium marinum (M.marinum) and the like.
[0055] Furthermore, the disease caused by nontuberculous mycobacteria is selected from one or more of NTM lung disease, NTM lymphatic disease, disseminated NTM disease and / or other NTM diseases.
[0056] Furthermore, the zuclopenthixol also includes pharmaceutically acceptable salts or esters.
[0057] Furthermore, the pharmaceutical salts include but are not limited to pharmaceutically acceptable salts such as acetate and hydrochloride.
[0058] Furthermore, the pharmaceutical esters include but are not limited to decanoate.
[0059] In a third aspect, the present invention provides an application of zuclopenthixol in combination with bedaquiline in the preparation of an anti-mycobacterial infection pharmaceutical composition, wherein the combination of zuclopenthixol and bedaquiline exerts an anti-mycobacterial infection effect, and the zuclopenthixol can enhance the anti-mycobacterial infection activity of bedaquiline.
[0060] Furthermore, the mycobacterium is selected from Mycobacterium tuberculosis, non-tuberculous mycobacteria and / or Mycobacterium leprae.
[0061] Furthermore, the Mycobacterium tuberculosis includes clinical isolates of Mycobacterium tuberculosis, standard strains of Mycobacterium tuberculosis and / or Mycobacterium tuberculosis carried by patients infected with Mycobacterium tuberculosis.
[0062] Furthermore, the Mycobacterium tuberculosis infection includes: primary infection, secondary infection, extrapulmonary infection, and pulmonary infection.
[0063] Furthermore, the diseases caused by Mycobacterium tuberculosis include but are not limited to drug-resistant tuberculosis, non-drug-resistant tuberculosis, pulmonary tuberculosis, extrapulmonary tuberculosis, etc.
[0064] Furthermore, the drug-resistant tuberculosis includes but is not limited to mono-drug-resistant tuberculosis, multi-drug-resistant tuberculosis, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis.
[0065] Furthermore, the pulmonary tuberculosis includes primary pulmonary tuberculosis, secondary pulmonary tuberculosis, blood type disseminated pulmonary tuberculosis, tracheobronchial tuberculosis, tuberculous pleurisy, septic tuberculosis, etc.
[0066] Furthermore, the extrapulmonary tuberculosis includes but is not limited to lymph node tuberculosis, intestinal tuberculosis, renal tuberculosis, bone and joint tuberculosis, etc.
[0067] Furthermore, the Mycobacterium tuberculosis includes multidrug-resistant Mycobacterium tuberculosis and extensively drug-resistant Mycobacterium tuberculosis.
[0068] Furthermore, the Mycobacterium tuberculosis includes Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium cannabinum and Mycobacterium microti.
[0069] Furthermore, the non-tuberculous mycobacteria include but are not limited to Mycobacterium avium (M.avium), Mycobacterium intracellulare (M.intracellulare), Mycobacterium kansasii (M.kansasii), Mycobacterium fortuitum (M.fortuitum), Mycobacterium abscessus (M.abscessus), Mycobacterium ulcerans (M.ulcerans) and / or Mycobacterium marinum (M.marinum) and the like.
[0070] Furthermore, the disease caused by nontuberculous mycobacteria is selected from one or more of NTM lung disease, NTM lymphatic disease, disseminated NTM disease and / or other NTM diseases.
[0071] Furthermore, the pharmaceutical composition may also contain other active ingredients against mycobacterial infection.
[0072] Furthermore, one or more pharmaceutically acceptable carriers may be added to the pharmaceutical composition.
[0073] Furthermore, the pharmaceutical composition can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral solution, injection preparation or aerosol; the above various dosage forms of drugs can be prepared according to conventional methods in the pharmaceutical field.
[0074] Furthermore, the preparation can be one or more of a conventional preparation, a sustained-release preparation, a controlled-release preparation and / or various microparticle delivery systems.
[0075] Furthermore, the tablets may widely use various carriers known in the art, including one or more of diluents and absorbents, wetting agents and binders, disintegrants, disintegration inhibitors, absorption enhancers and / or lubricants.
[0076] Furthermore, the diluent and absorbent include, but are not limited to, one or more of starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose and / or aluminum silicate.
[0077] Furthermore, the wetting agent and adhesive include, but are not limited to, one or more of water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia gum slurry, gelatin slurry, sodium carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and / or polyvinyl pyrrolidone.
[0078] Furthermore, the disintegrant includes, but is not limited to, one or more of dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitan fatty acid ester, sodium dodecyl sulfate, methyl cellulose and / or ethyl cellulose.
[0079] Furthermore, the disintegration inhibitor includes but is not limited to sucrose, tristearin, cocoa butter and / or hydrogenated oil.
[0080] Furthermore, the absorption enhancer includes but is not limited to one or more of quaternary ammonium salts and / or sodium lauryl sulfate.
[0081] Furthermore, the lubricant includes, but is not limited to, one or more of talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin and / or polyethylene glycol.
[0082] Furthermore, the tablets can be further made into coated tablets, including sugar-coated tablets, film-coated tablets, enteric-coated tablets, double-layer tablets and multi-layer tablets.
[0083] Furthermore, the injectable preparation includes, but is not limited to, one or more of a solution, an emulsion, a lyophilized powder injection and / or a suspension.
[0084] Furthermore, the injectable preparation may use all diluents commonly used in the art, including but not limited to one or more of water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol and / or polyoxyethylene sorbitan fatty acid esters.
[0085] Furthermore, in order to prepare an isotonic injection solution, the injection preparation may be added with an appropriate amount of one or more of sodium chloride, glucose, glycerol, conventional cosolvents, buffers and / or pH regulators.
[0086] Furthermore, the various preparations may also add colorants, preservatives, spices, flavoring agents, sweeteners or other materials to the pharmaceutical preparations as needed.
[0087] Furthermore, the pharmaceutical composition can be introduced into the body by physical or chemical methods, such as intramuscularly, intradermally, subcutaneously or intravenously.
[0088] Furthermore, the zuclopenthixol also includes pharmaceutically acceptable salts or esters.
[0089] Furthermore, the pharmaceutical salts include but are not limited to pharmaceutically acceptable salts such as acetate and hydrochloride.
[0090] Furthermore, the pharmaceutical esters include but are not limited to decanoate.
[0091] Beneficial Effects
[0092] In the present invention, zuclopenthixol is used in combination with bedaquiline, showing a significant enhancement of the activity against mycobacterial infection:
[0093] Compared with bedaquiline alone, 2 μg / ml of zuclopenthixol combined with bedaquiline reduced the colony count of MmpL5-MmpS5 strains to varying degrees from 1 / 16 MIC to 2 MIC of bedaquiline.
[0094] Zuclopenthixol, as a synergist of bedaquiline, can enhance the activity of bedaquiline against mycobacterial infection:
[0095] The minimum inhibitory concentration of zuclopenthixol against Rv0678 mutant in vitro was 16μg / ml, and the minimum inhibitory concentration of BDQ against Rv0678 mutant in vitro was 1μg / mL. 1μg / ml of zuclopenthixol combined with BDQ reduced the MIC of Rv0678 mutant against BDQ from 1μg / ml to 0.03μg / ml (32-fold increase in efficacy), which was lower than the wild-type H37Rv MIC (0.06μg / ml), reversing BDQ resistance and further enhancing the activity against mycobacterial infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0096] Figure 1 Time-kill curves of zuclopenthixol (ZUC) combined with bedaquiline (BDQ) on Mycobacterium tuberculosis H37Rv.
[0097] Figure 2 Time-kill curves of zuclopenthixol (ZUC) combined with bedaquiline (BDQ) on the MmpL5-mmpS5 overexpressing strain of Mycobacterium tuberculosis.
[0098] Figure 3 Time-kill curves of different concentrations of bedaquiline (BDQ) on the MmpL5-MmpS5 overexpression strain.
[0099] Figure 4 Time-kill curve of different concentrations of zuclopenthixol (ZUC) combined with bedaquiline (BDQ) on the MmpL5-MmpS5 overexpression strain. DETAILED DESCRIPTION
[0100] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.
[0101] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0102] the term
[0103] Zuclopenthixol: Zuclopenthixol is a thioxanthene derivative and the cis isomer of clopenthixol. It works by blocking dopamine receptors and has significant antipsychotic and specific sedative effects. It is especially suitable for patients with schizophrenia. Zuclopenthixol has low acute and chronic toxicity, and no toxicity is found at therapeutic doses. There is no toxicity that needs special attention when used in women of childbearing age. It has no toxicity such as mutagenicity and carcinogenicity, and is especially suitable for elderly patients.
[0104] Bedaquiline (BDQ): Its chemical name is 1-(6-bromo-2-methoxyquinolin-3-yl)-4-dimethylamino-1-phenyl-2-(1-naphthyl)-2-butanol, and its trade name is Sirturo. It is a new type of diarylquinoline antimycobacterial drug. It inhibits the activity of the proton pump of the ATP synthase of Mycobacterium tuberculosis to affect the ATP synthesis of Mycobacterium tuberculosis, thereby exerting antibacterial and bactericidal effects. It is clinically used to treat multidrug-resistant pulmonary tuberculosis (MDR-PTB) in adults.
[0105] The synergist in the present invention refers to zuclopenthixol. When zuclopenthixol and bedaquiline are used in combination, the anti-mycobacterial infection activity of bedaquiline can be enhanced. The anti-tuberculosis ability of the pharmaceutical composition after zuclopenthixol and bedaquiline are combined is enhanced compared with the use of bedaquiline alone.
[0106] MIC (minimuminhibitory concentration): minimum inhibitory concentration is an indicator for measuring the antibacterial activity of antibacterial drugs. It refers to the lowest drug concentration that can inhibit the growth of pathogens in the culture medium after 7 to 10 days of in vitro culture of Mycobacterium tuberculosis. In vitro pharmacodynamic interactions refer to the evaluation of the interaction and effective dose of the research drugs, so as to determine the feasibility of further development as a drug for the treatment of tuberculosis. The commonly used quantitative method is the chessboard dilution method. Taking the interaction between two drugs as an example, the MIC of the two research drugs against Mycobacterium tuberculosis is first determined. According to the MIC value, the highest concentration is set as 2×MIC of the single drug, and then 2-fold dilutions are performed one by one (in the vertical and horizontal columns of the square array, respectively). Each tube (well) contains a mixture of different concentrations of the two drugs. Generally, 6 to 8 dilutions are designed. The initial inoculum is 5×105CFU / mL, incubated at 37℃ for 7 days, and the results are observed and the fractional inhibitory concentration index (FICI) is calculated. The FICI index is calculated by the formula (MIC when drug A is used in combination / MIC when drug A is measured alone) + (MIC when drug B is used in combination / MIC when drug B is measured alone). The FICI value is used to judge the effect as synergistic (≤0.5), additive (0.5-1), irrelevant (1-2) and antagonistic (>2). FICI is one of the pharmacodynamic (PD) parameters of antimicrobial drugs and is an indicator of the combined drug sensitivity of two antimicrobial drugs (when two antimicrobial drugs are used at the same time, four situations may occur: synergistic, additive, irrelevant and).
[0107] Time-Kill Curves can dynamically observe the interaction between drugs (compounds) and Mycobacterium tuberculosis, and can compare the effects of different concentrations of compounds on the growth of Mycobacterium tuberculosis at different action times, providing more basis for evaluating the activity of compounds against mycobacterial infection. The experimental cycle of the time-kill curve is usually 14 days. Mycobacterium tuberculosis is cultured continuously in a drug-containing culture medium for 14 days. During this period, part of the bacterial solution is taken every 3-4 days and cultured on a solid culture medium. The colony count is performed after 3-4 weeks of culture. The time-kill curve is drawn with the time point of taking the bacterial solution as the horizontal axis (x-axis) and the Log10 of the colony count result as the vertical axis (y-axis). Time-kill curves are also used to evaluate the interaction between drugs in a drug combination in vitro.
[0108] Verapamil: A derivative of papaverine, commonly used as its hydrochloride, white powder; odorless. Easily soluble in methanol, ethanol or chloroform, soluble in water. Melting point 140℃~145℃. It was used as a coronary vasodilator in 1962. Verapamil, also known as verapamil and verapamil, is a calcium channel blocker. In recent years, it has been used to treat hypertension, angina pectoris, arrhythmia, cerebrovascular disease, finger vasospasm, abdominal pain, esophageal achalasia, migraine, pulmonary hypertension and prevent premature birth.
[0109] Example
[0110] Example 1 Screening of Zuclopenthixol
[0111] The Rv0678 mutant (MmpL5-MmpS5 overexpression) of Mycobacterium tuberculosis (Rv0678 mutant: BDQMIC=1 μg / ml) was used as a functional screening model to screen compounds that can reduce the MIC of bedaquiline from the drug library.
[0112] From the screening of 4000 compound libraries, zuclopenthixol was found to have the best activity against mycobacterial infection by enhancing bedaquiline, and its structural formula is as follows:
[0113]
[0114] Example 2 Determination of the minimum inhibitory concentration and combined synergistic activity of zuclopenthixol by MABA method
[0115] 2.1 Test content
[0116] In this part, the microplate Alamar Blue assay (MABA) was used to determine the minimum inhibitory concentration.
[0117] Add culture medium and drug stock solution to the microwells:
[0118] Weigh the drug powder and dissolve the fat-soluble drug in DMSO to make the drug stock solution concentration 2 mg / ml. Take the Mycobacterium tuberculosis bacterial solution and culture medium in the logarithmic growth phase and place them in the well plate. Measure the OD value of each well at a wavelength of 570 nm, where OD (strain) = OD (bacterial solution) - OD (7H9 culture medium). OD = 0.1 is equivalent to 1×10 7 CFU / mL, dilute each bacterial solution so that the final concentration of each strain is set to 1×10 5 CFU / mL.
[0119] The drugs in the first column of microwells were diluted to the tenth column by two-fold dilution method, and the final concentration of bacterial solution in each microwell was 1×10 5CFU / mL. On the 7th day of culture, Tween-80 solution and 20Alamar blue indicator were added to each microwell and the incubation continued. The color change was observed the next day, and the fluorescence value of each well was measured at 530nm and 590nm excitation wavelengths, and the color of each well was recorded. Blue indicated no growth of the strain, and red indicated bacterial growth; MIC indicated the lowest drug concentration at which the blue turned into red.
[0120] The combined activity was determined by the MIC method, except that after adding 1 μg / mL zuclopenthixol or 10 μg / mL verapamil to the culture medium at a final concentration of 1 μg / mL, the subsequent operation was performed with the culture medium containing 1 μg / mL zuclopenthixol or 10 μg / mL verapamil. The first 6 wells were used as negative control wells, and the diluted bacterial solution was added to the last 6 wells as positive control wells. Then, 198 μL of the culture medium containing 1 μg / mL zuclopenthixol or 10 μg / mL verapamil was added to the first column of microwells in the BH row of the 96-well plate, and 100 μL of the culture medium containing 1 μg / mL zuclopenthixol or 10 μg / mL verapamil was added to the remaining microwells. 2 μL of BDQ stock solution was added to the first column of microwells in the BH row, and the drug solution and the culture medium containing 1 μg / mL zuclopenthixol or 10 μg / mL verapamil were mixed, and the operation was repeated to the last column of microwells by two-fold dilution. Thus, the MIC of bedaquiline and the reduction factor were determined in combination with fixed concentrations of zuclopenthixol or verapamil.
[0121] 2.2 Test results
[0122] The minimum inhibitory concentration of zuclopenthixol against the Rv0678 mutant in vitro was 16 μg / ml, and the minimum inhibitory concentration of BDQ against the Rv0678 mutant in vitro was 1 μg / mL (as shown in Table 1). 1 μg / ml of zuclopenthixol combined with BDQ reduced the MIC of the Rv0678 mutant against BDQ from 1 μg / ml to 0.03 μg / ml (32-fold increase in efficacy), which was lower than the wild-type H37Rv MIC (0.06 μg / ml), reversing BDQ resistance and further enhancing the activity against mycobacterial infection, while 10 μg / ml of the efflux pump inhibitor verapamil had no effect on the MIC of BDQ in the Rv0678 mutant (as shown in Table 1).
[0123] Table 1 Zuclopenthixol enhances the activity of bedaquiline against the Rv0678 mutant
[0124]
[0125] Note: MIC of BDQ against wild-type H37Rv (0.06 μg / ml)
[0126] Example 3 Determination of the combined activity of zuclopenthixol and different anti-tuberculosis drugs against different strains by chessboard method
[0127] 3.1 Test content
[0128] The in vitro activity of zuclopenthixol combined with different anti-tuberculosis drugs and the activity of zuclopenthixol combined with Mycobacterium tuberculosis with different susceptibility to bedaquiline were determined by the checkerboard method.
[0129] Based on the MIC of each drug when applied alone, a total of 7 concentration gradients were set up with a concentration range of 4×MIC-1 / 16×MIC. The drugs were distributed in a checkerboard manner, as shown in Table 2. In a 96-well plate, X1-X7 were drug A (zuclopenthixol: ZUC) with a concentration of 4×MIC-1 / 16×MIC, and Y1-Y7 were drug B (bedaquiline: BDQ; isoniazid: INH; PA-824; moxifloxacin: MXF and linezolid: LZD) with a concentration of 4×MIC-1 / 16×MIC. Drug A was diluted two-fold vertically, and drug B was diluted two-fold horizontally. Columns A9-H9 and A10-H10 were negative control wells and positive control wells, respectively (as shown in Table 2).
[0130] After 7 days of culture, Alamar Blue indicator was added. After 24 hours, the color changes of drug A and drug B were observed to determine their respective MIC wells. The combined effect of the two drugs was determined by calculating the FICI value according to the calculation formula:
[0131] FICI=MICA combined / MICA alone+MICB combined / MICB alone
[0132] Among them, MICA alone and MICB alone respectively represent the MIC of drug A and drug B applied alone against Mycobacterium tuberculosis, and MICA combination and MICB combination respectively represent the minimum concentrations of drug A and drug B that prevent the color from changing from blue to pink after the combined application of drug A and drug B.
[0133] Table 2 Two-dimensional chessboard design
[0134]
[0135] Note: X is drug A, i.e. zuclopenthixol: ZUC; X1-X7 are 7 concentration gradients of zuclopenthixol: 4×MIC-1 / 16×MIC;
[0136] Y is drug B, which are bedaquiline: BDQ; isoniazid: INH; PA-824; moxifloxacin: MXF and linezolid: LZD; Y1-Y7 are 7 concentration gradients of drug B: 4×MIC-1 / 16×MIC.
[0137] 3.2 Test results
[0138] The chessboard assay showed that zuclopenthixol and BDQ had the best in vitro synergistic anti-mycobacterial activity against the Rv0678 mutant strain, with FICI = 0.156. In addition to the synergistic anti-tuberculosis effect with BDQ, zuclopenthixol had no interaction with anti-tuberculosis drugs such as isoniazid (INH), PA-824, moxifloxacin (MXF), and linezolid (LZD) (as shown in Table 3).
[0139] Table 3 Activity of the combined action of zuclopenthixol and anti-tuberculosis drugs on Rv0678 mutant strains
[0140]
[0141] Note: When the MIC of BDQ alone is 1μg / mL and the MIC of the combination is 0.03125μg / mL, the concentration of zuclopenthixol is 2μg / mL; when the MIC of INH alone is 0.04μg / mL and the MIC of the combination is 0.00125μg / mL, the concentration of zuclopenthixol is 16μg / mL; when the MIC of PA-824 alone is 0.16μg / mL and the MIC of the combination is 16μg / mL, the concentration of zuclopenthixol is 16μg / mL; when the MIC of MFX alone is 1μg / mL and the MIC of the combination is 0.03μg / mL, the concentration of zuclopenthixol is 16μg / mL; when the MIC of LZD alone is 0.29μg / mL and the MIC of the combination is 0.009μg / mL, the concentration of zuclopenthixol is 16μg / mL.
[0142] The activity of zuclopenthixol combined with bedaquiline was further determined on different bedaquiline-resistant strains, and the combined synergistic activity was studied on the constructed genetically engineered bacteria MmpL5-MmpS5 overexpression strain, the sensitive strain H37Rv, different Rv0678 mutants, and the bedaquiline target gene atpE mutant.
[0143] The interaction was determined by the chessboard method and it was found that zuclopenthixol and bedaquiline had synergistic activity in all tested strains, but the synergistic activity in the Rv0678 mutant strain and the MmpL5-MmpS5 overexpression strain was better than that in the H37Rv strain and the atpE mutant strain (as shown in Table 4).
[0144] Table 4 Activity of zuclopenthixol combined with bedaquiline against mycobacterial infection in different strains
[0145]
[0146] Note: For H37Rv standard strain, when the MIC of BDQ alone was 0.06μg / mL and the MIC of the combination was 0.015μg / mL, the concentration of zuclopenthixol was 2μg / mL; for MmpL5-MmpS5 overexpressing bacteria, when the MIC of BDQ alone was 0.5μg / mL and the MIC of the combination was 0.03125μg / mL, the concentration of zuclopenthixol was 2μg / mL; for Rv0678 mutant strain 2, when the MIC of BDQ alone was 1μg / mL and the MIC of the combination was 0.0625μg / mL, the concentration of zuclopenthixol was 2μg / mL; for atpE mutant strain, when the MIC of BDQ alone was 1.25μg / mL and the MIC of the combination was 0.3125μg / mL, the concentration of zuclopenthixol was 8μg / mL.
[0147] Example 4 Evaluation of the antibacterial activity of a two-drug combination containing zuclopenthixol by time-kill curve method
[0148] 4.1 Test content
[0149] In order to investigate the dynamic bactericidal activity of zuclopenthixol combined with bedaquiline, a study on the bactericidal curve of combined action was conducted.
[0150] The evaluation of the two-drug combination of antimicrobial drugs included single-drug wells and two-drug combination wells. ZUC 10μg / mL and BDQ 1 / 2×MIC were selected for time-kill test evaluation.
[0151] Prepare drug and drug combination solutions of corresponding concentrations, add H37Rv or Rv0678 mutant bacterial solution, and make the concentration of each bacterial solution reach 2×10 5 CFU / mL, culture. On the day of culture (D0) and on the 3rd, 7th, 10th, and 14th days of culture, the original bacterial solution or the diluted bacterial solution was aspirated from the 24-well plate and inoculated on the solid culture medium, spread evenly, and the colonies were counted after 4 weeks of culture. The time-killing curves of the combination of zuclopenthixol and bedaquiline were drawn with the culture time point of Mycobacterium tuberculosis as the abscissa and the logarithm of the colony count at different culture time points as the ordinate.
[0152] 4.2 Test results
[0153] Zuclopenthixol at 10 μg / ml combined with bedaquiline at 1 / 2 MIC can exert anti-mycobacterial activity against H37Rv and MmpL5-MmpS5 overexpressing strains, while either zuclopenthixol at 10 μg / ml or bedaquiline at 1 / 2 MIC alone has no bactericidal activity (e.g. Figure 1 shown).
[0154] The bactericidal effect of zuclopenthixol combined with bedaquiline on the Rv0678 mutant was more obvious, reaching sterility in 10 days, while it took 14 days to achieve sterility for H37Rv (e.g. Figure 2 shown).
[0155] Further reducing the concentration of zuclopenthixol and combining it with different concentrations of bedaquiline to act on the MmpL5-MmpS5 strains, it was found that compared with bedaquiline alone (such as Figure 3 As shown in Figure 2), 2 μg / ml of zuclopenthixol combined with bedaquiline reduced the colony count of MmpL5-MmpS5 strains to varying degrees from 1 / 16 MIC to 2 MIC of bedaquiline, showing a significant enhancement of the activity against mycobacterial infection (as shown in Figure 2). Figure 4 shown).
Claims
1. A pharmaceutical composition for preventing mycobacterial infection, comprising zuclopenthixol and bedaquiline, wherein the pharmaceutical composition has at least one of the following effects: a) inhibiting mycobacterial activity; b) Anti-mycobacterial infection; c) prevention and / or treatment of diseases caused by mycobacteria.
2. An application of zuclopenthixol in combination with bedaquiline in the preparation of an anti-mycobacterial infection pharmaceutical composition, wherein the combination of zuclopenthixol and bedaquiline exerts an anti-mycobacterial infection effect, and the zuclopenthixol can enhance the anti-mycobacterial infection activity of bedaquiline.
3. The pharmaceutical composition as claimed in claim 1 or 2 can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral solution, injection preparation or aerosol; the above various dosage forms of drugs can be prepared according to conventional methods in the pharmaceutical field.
4. As claimed in claim 3, colorants, preservatives, spices, flavoring agents, sweeteners or other materials can also be added to the pharmaceutical preparations as needed.
5. The pharmaceutical composition according to any one of claims 1 to 3, further comprising other active ingredients against mycobacterial infection.
6. The pharmaceutical composition according to any one of claims 1 to 3, further comprising one or more pharmaceutically acceptable carriers.
7. The pharmaceutical composition according to any one of claims 1 to 3 can be introduced into the body by physical or chemical methods, such as intramuscularly, intradermally, subcutaneously or intravenously.
8. A use of zuclopenthixol as a synergist of bedaquiline's anti-mycobacterial infection effect. When zuclopenthixol is used in combination with bedaquiline, zuclopenthixol can enhance the anti-mycobacterial infection activity of bedaquiline.
9. The mycobacterium according to any one of claims 1 to 7 is selected from Mycobacterium tuberculosis, nontuberculous mycobacteria and / or Mycobacterium leprae.
10. The zuclopenthixol according to any one of claims 1 to 7 further comprises a pharmaceutically acceptable salt or ester, wherein: The pharmaceutical salts include but are not limited to pharmaceutically acceptable salts such as acetate and hydrochloride; the pharmaceutical esters include but are not limited to decanoate.
Citation Information
Patent Citations
Pharmaceutical composition suitable for treating drug-resistant tuberculosis
CN114081886A
Pharmaceutical composition and application thereof
CN115350194A
Pharmaceutical composition for treating tuberculosis
CN115531388A
Cited By
Combined synergistic pharmaceutical composition for resisting mycobacterial infection
CN119564683A
A synergistic pharmaceutical composition for resisting mycobacterial infection
CN119564683B
Mycobacterium mardellii and application thereof in developing sewage treatment
CN120738074A
